Cargando…

Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue

BACKGROUND: Leber's congenital amaurosis (LCA) is a severe form of retinal dystrophy. Mutations in the RPE65 gene, which is abundantly expressed in retinal pigment epithelial (RPE) cells, account for approximately 10–15% of LCA cases. In this study we used the high turnover, and rapid breeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Chooi-May, Yu, Meaghan JT, Brankov, Meliha, Barnett, Nigel L, Zhou, Xiaohuai, Redmond, T Michael, Narfstrom, Kristina, Rakoczy, P Elizabeth
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC416492/
https://www.ncbi.nlm.nih.gov/pubmed/15109394
http://dx.doi.org/10.1186/1479-0556-2-3
_version_ 1782121424377348096
author Lai, Chooi-May
Yu, Meaghan JT
Brankov, Meliha
Barnett, Nigel L
Zhou, Xiaohuai
Redmond, T Michael
Narfstrom, Kristina
Rakoczy, P Elizabeth
author_facet Lai, Chooi-May
Yu, Meaghan JT
Brankov, Meliha
Barnett, Nigel L
Zhou, Xiaohuai
Redmond, T Michael
Narfstrom, Kristina
Rakoczy, P Elizabeth
author_sort Lai, Chooi-May
collection PubMed
description BACKGROUND: Leber's congenital amaurosis (LCA) is a severe form of retinal dystrophy. Mutations in the RPE65 gene, which is abundantly expressed in retinal pigment epithelial (RPE) cells, account for approximately 10–15% of LCA cases. In this study we used the high turnover, and rapid breeding and maturation time of the Rpe65(-/- )knockout mice to assess the efficacy of using rAAV-mediated gene therapy to replace the disrupted RPE65 gene. The potential for rAAV-mediated gene treatment of LCA was then analyzed by determining the pattern of RPE65 expression, the physiological and histological effects that it produced, and any improvement in visual function. METHODS: rAAV.RPE65 was injected into the subretinal space of Rpe65(-/- )knockout mice and control mice. Histological and immunohistological analyses were performed to evaluate any rescue of photoreceptors and to determine longevity and pattern of transgene expression. Electron microscopy was used to examine ultrastructural changes, and electroretinography was used to measure changes in visual function following rAAV.RPE65 injection. RESULTS: rAAV-mediated RPE65 expression was detected for up to 18 months post injection. The delivery of rAAV.RPE65 to Rpe65(-/- )mouse retinas resulted in a transient improvement in the maximum b-wave amplitude under both scotopic and photopic conditions (76% and 59% increase above uninjected controls, respectively) but no changes were observed in a-wave amplitude. However, this increase in b-wave amplitude was not accompanied by any slow down in photoreceptor degeneration or apoptotic cell death. Delivery of rAAV.RPE65 also resulted in a decrease in retinyl ester lipid droplets and an increase in short wavelength cone opsin-positive cells, suggesting that the recovery of RPE65 expression has long-term benefits for retinal health. CONCLUSION: This work demonstrated the potential benefits of using the Rpe65(-/- )mice to study the effects and mechanism of rAAV.RPE65-mediated gene delivery into the retina. Although the functional recovery in this model was not as robust as in the dog model, these experiments provided important clues about the long-term physiological benefits of restoration of RPE65 expression in the retina.
format Text
id pubmed-416492
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-4164922004-05-23 Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue Lai, Chooi-May Yu, Meaghan JT Brankov, Meliha Barnett, Nigel L Zhou, Xiaohuai Redmond, T Michael Narfstrom, Kristina Rakoczy, P Elizabeth Genet Vaccines Ther Research BACKGROUND: Leber's congenital amaurosis (LCA) is a severe form of retinal dystrophy. Mutations in the RPE65 gene, which is abundantly expressed in retinal pigment epithelial (RPE) cells, account for approximately 10–15% of LCA cases. In this study we used the high turnover, and rapid breeding and maturation time of the Rpe65(-/- )knockout mice to assess the efficacy of using rAAV-mediated gene therapy to replace the disrupted RPE65 gene. The potential for rAAV-mediated gene treatment of LCA was then analyzed by determining the pattern of RPE65 expression, the physiological and histological effects that it produced, and any improvement in visual function. METHODS: rAAV.RPE65 was injected into the subretinal space of Rpe65(-/- )knockout mice and control mice. Histological and immunohistological analyses were performed to evaluate any rescue of photoreceptors and to determine longevity and pattern of transgene expression. Electron microscopy was used to examine ultrastructural changes, and electroretinography was used to measure changes in visual function following rAAV.RPE65 injection. RESULTS: rAAV-mediated RPE65 expression was detected for up to 18 months post injection. The delivery of rAAV.RPE65 to Rpe65(-/- )mouse retinas resulted in a transient improvement in the maximum b-wave amplitude under both scotopic and photopic conditions (76% and 59% increase above uninjected controls, respectively) but no changes were observed in a-wave amplitude. However, this increase in b-wave amplitude was not accompanied by any slow down in photoreceptor degeneration or apoptotic cell death. Delivery of rAAV.RPE65 also resulted in a decrease in retinyl ester lipid droplets and an increase in short wavelength cone opsin-positive cells, suggesting that the recovery of RPE65 expression has long-term benefits for retinal health. CONCLUSION: This work demonstrated the potential benefits of using the Rpe65(-/- )mice to study the effects and mechanism of rAAV.RPE65-mediated gene delivery into the retina. Although the functional recovery in this model was not as robust as in the dog model, these experiments provided important clues about the long-term physiological benefits of restoration of RPE65 expression in the retina. BioMed Central 2004-04-27 /pmc/articles/PMC416492/ /pubmed/15109394 http://dx.doi.org/10.1186/1479-0556-2-3 Text en Copyright © 2004 Lai et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research
Lai, Chooi-May
Yu, Meaghan JT
Brankov, Meliha
Barnett, Nigel L
Zhou, Xiaohuai
Redmond, T Michael
Narfstrom, Kristina
Rakoczy, P Elizabeth
Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue
title Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue
title_full Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue
title_fullStr Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue
title_full_unstemmed Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue
title_short Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65(-/- )knockout mouse eye results in limited rescue
title_sort recombinant adeno-associated virus type 2-mediated gene delivery into the rpe65(-/- )knockout mouse eye results in limited rescue
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC416492/
https://www.ncbi.nlm.nih.gov/pubmed/15109394
http://dx.doi.org/10.1186/1479-0556-2-3
work_keys_str_mv AT laichooimay recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue
AT yumeaghanjt recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue
AT brankovmeliha recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue
AT barnettnigell recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue
AT zhouxiaohuai recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue
AT redmondtmichael recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue
AT narfstromkristina recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue
AT rakoczypelizabeth recombinantadenoassociatedvirustype2mediatedgenedeliveryintotherpe65knockoutmouseeyeresultsinlimitedrescue